Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03660332
Other study ID # H-16036538
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2017
Est. completion date April 1, 2017

Study information

Verified date February 2024
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to investigate and clarify whether the effect of IL-6 on glucose tolerance and insulin secretion are secondary to the changes in gastric emptying. The literature provides no information regarding a role for interleukin-6 (IL-6) in the regulation of beta cell function (glucose or meal-stimulated insulin secretion) in humans. Previous studies infusing IL-6 into humans have primarily focused on insulin action and the effects on peripheral insulin sensitivity whereas a potential effect on insulin secretion has been neglected. We have demonstrated that an acute increase in IL-6, obtained by a single bolus of IL-6, potentiated glucose-induced insulin secretion in a glucagon-like peptide-1 (GLP-1) dependent manner in mice1. In mice, IL-6 enhanced insulin secretion in a dose- and glucose-dependent manner, along with increasing concentrations of GLP-1. Interleukin-6 had no effect on insulin secretion in GLP-1 receptor knock-out mice or in mice treated with the GLP-1 receptor antagonist. Thus, in mice, GLP-1 has proven an essential mediator of IL-6 actions on beta cell function. Importantly, a single bolus of IL-6 also significantly increased glucose-stimulated insulin secretion in several mouse models of obesity and diabetes (diet-induced obesity, the ob/ob and the db/db mouse). Own data show that an infusion of IL-6 causes a significant delay in the rate of gastric emptying (GE) after a mixed meal in healthy young men. Data showed that this delay in GE is associated with much improved glucose tolerance and insulin secretion (unpublished data). In the present study we wish to investigate whether the beneficial effects of IL-6 on postprandial glucose tolerance and insulin secretion are dependent on a delay in gastric emptying. We will bypass the ventricle and infuse a mixed meal directly into the duodenum of healthy young men. This study has the potential to show that the known effect of IL-6 on postprandial glucose tolerance is dependent on a delayed GE.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date April 1, 2017
Est. primary completion date April 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Age = 18 years and = 35 years - Healthy (based on screening) Exclusion Criteria: - Smoking - BMI < 18 and > 25 kg/m2 - Evidence of severe thyroid, liver, lung, heart or kidney disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Infusion of a liquid meal intraduodenally
Infusion of IL-6/NaCL before a liquid meal intraduodenally

Locations

Country Name City State
Denmark Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS) Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Lang Lehrskov L, Lyngbaek MP, Soederlund L, Legaard GE, Ehses JA, Heywood SE, Wewer Albrechtsen NJ, Holst JJ, Karstoft K, Pedersen BK, Ellingsgaard H. Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control. Cell Metab. 201 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The paracetamol uptake paracetamol blood levels (mmol/l) on both study days. The paracetamol absorbance will be compared between the 2 study days. 0-14 days
Secondary GLP-1 secretion Active GLP-1 blood levels on both study days. The levels on the 2 study days will be compared. 0-14 days
Secondary Glucagon secretion Glucagon blood levels on both study days. The levels on the 2 study days will be compared. 0-14 days
Secondary Insulin levels Insulin blood levels on both study days. The levels on the 2 study days will be compared. 0-14
Secondary Glucose Plasma glucose levels on both study days. The levels on the 2 study days will be compared. 0-14